Disclosed herein are methods and composition producing a viral vaccine with reduced particle size, particularly for use in the production of influenza virus vaccines.

The present disclosure provides compositions and methods related to antiviral therapeutics. In particular, the present disclosure provides novel compositions and methods for treating and/or preventing viral infections using vesicles derived from lung spheroid cells (LSCs). LSC-derived vesicles can be used as viral decoy nanoparticles for therapeutic applications, as virus-like particles (VLPs) for vaccine production, and as an antiviral drug delivery platform.

Disclosed herein are methods of forming compounds and exemplary compounds in the nature of a conjugated compound, which in some embodiments comprises an antigen and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV 2).

Methods of inducing an immunogenic response against a bacterial polysaccharide or oligosaccharide, and constructs and compositions for use in such methods.

Disclosed herein are methods of forming compounds and exemplary stable compounds in the nature of a conjugated compound at refrigerated or room temperature, which in some embodiments comprises an antigen and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV 2).

The present invention relates to a virus-like particle for preventing or treating toxoplasmosis, comprising influenza virus matrix protein 1; and surface antigen proteins comprising an inner membrane complex, Rhoptry protein 18 and Microneme protein 8 derived from Toxoplasma gondii, and a pharmaceutical composition comprising the same.

The present invention in particular relates to a method of producing an immunogenic composition exhibiting reduced virucidal activity, as well as to the immunogenic composition and uses thereof, wherein the method in particular comprises the steps of: (a) providing a mixture with a first liquid and a recombinant protein, (b) concentrating the recombinant protein in the mixture by removing a portion of the first liquid from the mixture, and (c) processing the solution resulting from step (b) by continuous diafiltration.

The present disclosure is directed to improved virus-like particle (VLP) compositions and vaccines for use in inducing an immune response and/or protective immunity against a Chikungunya virus (CHIKV) infection in a subject, e.g., by inducing a neutralizing antibody response against CHIKV in a subject within 7 days after administration of a single dose of the composition or vaccine.

The present disclosure relates to hybrid hepadnavirus core antigens including one or more epitopes of a human hepatitis B vims (HBV) antigen. More specifically, the present disclosure relates to hybrid hepadnavirus core antigens in the form of fusion proteins containing a fragment of the PreS1 region of the HBV surface antigen inserted in a woodchuck hepadnavirus core antigen. The present disclosure further relates to hybrid hepadnavirus core antigens in the form of fusions proteins containing a truncated HBV core antigen and woodchuck hepadnavirus core antigen. Also provided are nucleic acids encoding the hybrid core antigens, and the use of the hybrid core antigens and nucleic acids for treating HBV-infected individuals.

Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.